# The Safety and Efficacy of Biolimus in the Treatment of Patients With in Stent Restenosis

Study · id `cardio:ct-nct04733443` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04733443](<https://clinicaltrials.gov/study/NCT04733443>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04733443

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 310 participants.

## Technical summary

Registry record NCT04733443. Randomized; no masking; primary purpose treatment. Start 2020-12-17 (actual); primary completion 2023-01-18 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 310 participants (enrolled count; ClinicalTrials.gov record NCT04733443, source copy `cardio:ctgov-nct04733443-2023-11-18`, retrieved 2026-10-26)
- Started: 2020-12-17 (actual) (ClinicalTrials.gov record NCT04733443, source copy `cardio:ctgov-nct04733443-2023-11-18`, retrieved 2026-10-26)
- Primary completion: 2023-01-18 (actual) (ClinicalTrials.gov record NCT04733443, source copy `cardio:ctgov-nct04733443-2023-11-18`, retrieved 2026-10-26)
- Completion: 2025-02-18 (anticipated) (ClinicalTrials.gov record NCT04733443, source copy `cardio:ctgov-nct04733443-2023-11-18`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT04733443, source copy `cardio:ctgov-nct04733443-2023-11-18`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04733443-2023-11-18`, retrieved 2026-10-26)

## The registry's words

- Brief title: The Safety and Efficacy of Biolimus in the Treatment of Patients With in Stent Restenosis
- Condition: Coronary Artery Disease
- Intervention (Device): Biolimus
- Intervention (Device): SeQuent® Please Neo
- Lead sponsor: JW Medical Systems Ltd
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: JW Medical Systems Ltd (`cardio:org-jw-medical-systems-ltd`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Biolimus-coated versus paclitaxel-coated balloons for coronary in-stent restenosis (BIO ASCEND ISR): a randomised, non-inferiority trial (`cardio:pubmed-38742581`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: ab755d39653d6620c78e77c11ae8fa278545b419952371498db3f0eb06b266e3
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
